stockrowCibus, Inc. (CBUS) vs ImmuCell Corporation (ICCC)
- Cibus, Inc. CBUS 1.17 +2.63%
- ImmuCell Corporation ICCC 9.90 −0.50%
Cibus, Inc. and ImmuCell Corporation are both Biotechnology companies. Cibus, Inc. and ImmuCell Corporation are of similar size ($90.4M and $87.1M). Cibus, Inc. has negative trailing earnings, so its P/E is not meaningful; ImmuCell Corporation trades at 117×. ImmuCell Corporation grew revenue faster over the last twelve months: 8.49% against −10.3%. ImmuCell Corporation has the higher net margin (2.57% vs −2,258.9%) and the higher return on invested capital (7.84% vs 0.00%). Across the 18 metrics below, ImmuCell Corporation leads on 14 and Cibus, Inc. on 4.
Valuation
Profitability
| Metric | CBUS | ICCC | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 40.32% | 68.51% |
| Operating margin | (1,450.59%) | 12.60% | 0.00% |
| Net margin | (2,258.89%) | 2.57% | 0.00% |
| Free cash flow margin | (1,064.60%) | 13.79% | 0.00% |
| Return on equity | (219.97%) | 2.57% | (51.96%) |
| Return on assets | (29.77%) | 1.69% | (46.06%) |
| Return on invested capital | 0.00% | 7.84% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack